SG Americas Securities
AYTU icon

SG Americas Securities’s AYTU BioPharma AYTU Stock Holding History

SG Americas Securities’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-62
Closed -$18K – 2724
2020
Q2 		$18K Buy
+62
New +$18.8K ﹤0.01% 3611

Other funds holding AYTU

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

SG Americas Securities's AYTU Position: Q3 2020 in Review

SG Americas Securities sold out of AYTU BioPharma (AYTU) in Q3 2020, closing a stake of 62 shares — an estimated $18K sold.

SG Americas Securities first reported a position in AYTU in Q2 2020 and held it in 1 quarter. The position peaked at $18K in Q2 2020. 57 funds tracked by Wall St. Rank hold AYTU as of Q3 2020.

  • SG Americas Securities reported no remaining AYTU BioPharma position as of Q3 2020 after selling out during the quarter.
  • SG Americas Securities sold 62 AYTU BioPharma shares in Q3 2020, an estimated $18K.
  • SG Americas Securities first reported a position in AYTU BioPharma in Q2 2020 and held it in 1 quarter.
  • SG Americas Securities's AYTU BioPharma position peaked at $18K in Q2 2020.
  • 57 funds tracked by Wall St. Rank held AYTU BioPharma as of Q3 2020.

Based on SG Americas Securities's 13F filing for Q3 2020, filed 9 Nov 2020.